V-IOTIC & the Importance of a Healthy Gut Microbiome
Share
V-IOTIC & the Importance of a Healthy Gut Microbiome
Bloating. Constipation. Abdominal discomfort. Your gut microbiome is at the centre of it all — and the strains in V-IOTIC have been studied in exactly that context.
By the V-IOTIC Team
Most people are aware that gut health matters. Far fewer know which probiotic strains have actually been studied for gut-specific outcomes — and what the clinical data behind them really shows.
V-IOTIC is known as a vaginal-first formula — but the gut microbiome is not separate from that story. Three of the five strains in V-IOTIC are drawn from the SynbÆctive® SmilinGut complex, a clinically studied combination researched specifically for gastrointestinal health. This is not a coincidence. The gut and vaginal microbiomes are connected ecosystems, and supporting one has direct relevance to the other.
This article focuses on the gut side of that story — what the SmilinGut clinical data shows, what the strains were studied for, and why traceable, evidence-led strain selection matters as much in gut health as it does in vaginal health.
The Basics
What Is the Gut Microbiome — and Why Does It Keep Coming Up?
The gut microbiome is the vast community of microorganisms that live throughout your digestive tract. It plays a role in digestion, nutrient absorption, immune regulation, inflammation, and — increasingly — mood and hormonal balance.
Digestion & Comfort
A balanced gut microbiome supports normal digestive function — reducing bloating, regulating transit time, and helping manage the discomfort of a disrupted gut.
Immune Function
Around 70% of the immune system is housed in the gut. Probiotic strains in the gut microbiome help regulate immune responses and inhibit harmful pathogens from establishing themselves.
The Gut-Vaginal Axis
The gut and vaginal microbiomes are not isolated. Lactobacillus strains that colonise the gut can migrate and influence the vaginal environment — which is why gut-studied strains belong in a vaginal-first formula.
When the gut microbiome is disrupted — by diet, stress, antibiotics, illness or lifestyle — the consequences extend beyond digestion. Immune resilience drops, inflammation can increase, and the conditions for recurring issues elsewhere in the body become more likely.
The Strains
Three Traceable Strains. One Studied Complex.
The SmilinGut complex contains three specific, patented SynbÆctive® strains — each one present in V-IOTIC with a traceable code and a published evidence base. This is not a generic multi-strain blend. Every strain was selected for a specific, documented reason.
3 Strains
15B CFU
Total formula
L. plantarum PBS067 · L. rhamnosus LRH020 · B. animalis subsp. lactis BL050
These three strains form the gut-studied core of the V-IOTIC formula. Each carries a specific strain code — not just a species name — and has been studied together as a complex in a randomised, double-blind, placebo-controlled clinical trial. Their presence in V-IOTIC is traceable, intentional and evidence-led.
Many gut probiotics on the market list species names — Lactobacillus plantarum, Lactobacillus rhamnosus — without a strain code. A species name alone gives you no way to verify the research behind that specific strain, because thousands of strains exist within each species and they do not all behave the same way. PBS067, LRH020 and BL050 are specific, patented and studied. That is the difference.
How the Strains Work
Protecting the Gut From Within
In vitro research — published in Applied Microbiology and Biotechnology 2015 — studied the SmilinGut strains against three of the most common enteric pathogens. The results were assessed using an overlay assay measuring inhibition, with competitive and metabolite-mediated mechanisms both evaluated.
Escherichia coli
All three SmilinGut strains demonstrated strong inhibitory activity against E. coli — one of the most common causes of gut infection and digestive disruption.
Enterococcus faecalis
The strains showed significant competitive inhibition against E. faecalis, with synergic effects observed when strains were combined — demonstrating the value of a multi-strain approach.
Staphylococcus aureus
Strong acidic metabolite-mediated inhibition was observed against S. aureus, with the strains producing short-chain fatty acids and bacteriocins that compete with the pathogen.
The strains also demonstrated anti-inflammatory and antioxidant activity in vitro — showing significant effects on pro-inflammatory cytokines TNF-α and anti-inflammatory markers IL-4 and IL-10. This supports the idea that these strains do not just compete with pathogens — they actively support the gut's immune environment.
What It Addresses
The Gut Symptoms the Clinical Study Measured
The clinical study behind SmilinGut used a VAS Visual Analogue Scale symptom scoring system across five specific markers — all measured at regular intervals over 90 days including a 30-day washout period. These are the symptoms most commonly associated with gut microbiome disruption and IBS-C like presentations.
Bloating
Abdominal swelling and distension — one of the most common and disruptive gut symptoms, measured from baseline through the full study and washout period.
Flatulence
Excess gas and wind — assessed alongside bloating as part of the broader picture of gut fermentation and microbiome imbalance.
Abdominal Pain
General abdominal discomfort — a central symptom in IBS and gut dysbiosis, tracked consistently across the study timeline.
Abdominal Cramps
Cramping distinct from general pain — measured separately to capture the spasmodic discomfort associated with bowel irregularity.
Constipation
Infrequent or difficult bowel movements — a defining feature of IBS-C and a common consequence of gut microbiome disruption.
The Clinical Evidence
What the SmilinGut Study Reported
The clinical study was a randomised, double-blind, placebo-controlled trial of 50 subjects over 60 days, with stool collection, PCR analysis and VAS symptom questionnaires at T0, T10, T30, T60 and T90 including a 30-day washout. Published in BioMed Research International 2016, it is the gold standard in clinical research methodology.
Good results across all symptom indicators from day 10
The study reported meaningful improvements in bloating, flatulence, abdominal pain, abdominal cramps and constipation beginning at just 10 days — the first measurement point after baseline. All five symptom scores showed a downward trend in the active group from T10 onwards, with no significant change in the placebo group.
Subjects self-reported over 30% improvement in symptoms
Using self-assessment scoring, subjects in the active group declared over 30% improvement in their symptoms — a clinically meaningful threshold used to define a positive treatment response in IBS research. This was a consistent finding across the study period.
Selective, consistent GI colonisation of all administered strains
PCR analysis of stool samples confirmed selective, consistent and significant colonisation of the gut for all three administered strains in the active group p<0.01. No significant increase was observed in the placebo group for any strain. This confirms that these specific strains survive and colonise the GI tract — not just pass through it.
Long-term effect persisted after end of treatment
At T90 — 30 days after the supplementation period ended — the active group's symptom scores remained consistently lower than both the placebo group and their own baseline values p<0.001. This long-term effect after cessation of treatment is a strong indicator that the strains produced lasting changes in the gut environment, not just temporary symptom relief.
The Bigger Picture
Why Gut Health Belongs in a Vaginal-First Formula
V-IOTIC is vaginal-first — but that does not mean gut health is secondary. It means every strain was selected with a specific, evidenced purpose, and the gut-studied strains in the formula serve a dual role.
L. plantarum PBS067 and L. rhamnosus LRH020 appear in both the SmilinGut and Femme clinical complexes. They have been studied in the gut for digestive symptom relief and colonisation, and studied in the vaginal environment for microbiome restoration and intimate health outcomes. These are not two separate functions — they are the same strains, studied across both ecosystems.
B. animalis subsp. lactis BL050 contributes to gut microbiome diversity and has demonstrated anti-inflammatory activity in the gut lining. A healthier gut environment supports immune regulation more broadly — including in the vaginal tract.
The inclusion of a GOS prebiotic 700mg in V-IOTIC feeds both the gut and vaginal strains simultaneously — sustaining colonisation across both ecosystems and making V-IOTIC a true synbiotic in the fullest sense of the word.
Set Realistic Expectations
How Long Does It Take?
10+
Days to first results — 60 days for full clinical benefit
The SmilinGut clinical study showed meaningful symptom improvements from as early as day 10, with the full study running over 60 days. Crucially, the long-term effect persisted 30 days after supplementation ended — which means the strains were not just providing temporary relief, but building lasting changes in the gut microbiome.
Consistency is everything. The strains need time to colonise, compete and establish themselves in the gut environment. A minimum of 10 days is required to see early movement, but the most meaningful and lasting outcomes in the clinical data appeared at 30, 60 and 90 days of consistent daily use.
When we created V-IOTIC, we didn't want another generic probiotic blend. We wanted clinically studied, traceable strains — selected with purpose.
Because women deserve to know exactly what they're taking and why.
This is Part 2 of the V-IOTIC Science Series, based on the SynbÆctive® SmilinGut clinical data. Part 1 covers the Femme vaginal microbiome data. Part 3 covers the ProBeautyShield skin health data.
Ready to start?
15 Billion CFU. 5 Patented Strains.
Gut support built in.
Clinically studied strains, traceable codes, and a formula where every ingredient has a specific, evidenced reason for being there.
Shop V-IOTIC 60 capsules · 30-day supply · Free UK deliveryV-IOTIC is a food supplement. Food supplements should not replace a varied and balanced diet and healthy lifestyle.
Zinc contributes to the normal function of the immune system. Biotin contributes to normal macronutrient metabolism and the maintenance of normal skin and hair. These are authorised EU/GB nutrition and health claims per the GB NHC Register.
The clinical studies referenced in this article relate to the SynbÆctive® SmilinGut strain complex by SynBalance and have been published in peer-reviewed journals including Applied Microbiology and Biotechnology 2015 and BioMed Research International 2016. V-IOTIC is formulated using these patented strains under licence. Full study references are available on request.